We currently use the HiQCell system to obtain our MSCs. Thus far we have focussed on musculoskeletal conditions involving damaged joints, tendons and cartilage for treatment with stem cells.
- On a study done by our clinic on the first 67 osteoarthritis patients treated with adipose-SVF and assessed each month for 6 months reported that over 80% of patients treated show a significant improvement of between 50 - 100% in pain and mobility of the joint.
- On average, responders had a 60% decrease in pain scores in the first 2 weeks.
- The repair process takes time - with the improvement at its maximum level by 6 months
- Whether young or old the improvement by stem cell therapy was the same.
- It is too early to determine the lifespan of the treatment as this treatment has only been available since 2009.
Osteoarthritis (OA) is the most common joint disorder in the world. In Australia, 1 in 5 suffer from some form of osteoarthritis affecting almost 5 million people. The potential cost to the Australian economy is around 24 billion dollars. OA is a degenerative joint disease characterised by loss of articular cartilage in synovial joints. It can be defined by joint symptoms (pain and stiffness), by hyaluronic acidstructural pathology (x-rays and MRI) or by a combination of the two.
Current treatments for OA aim at reducing symptoms of pain and stiffness. These can include: paracetamol, fish oils, glucosamine, NSAIDs, cortisone injections, hyaluronic acid. Non pharmaceutical treatments include weight loss, diet, physiotherapy and exercise. Joint replacement surgery has inherent risks, a significant recovery and rehab process and a finite life expectancy of 10-15 yrs.